A plain-language explainer of flat-rate (dose-independent) pricing, how it differs from dose-tiered pricing, and when each one saves you money.
Flat-rate (dose-independent) compounded tirzepatide pricing is a model where you pay the same monthly price regardless of your prescribed dose — whether your clinician has you at 2.5 mg or 15 mg weekly. This contrasts with dose-tiered pricing, where the monthly cost rises as the dose increases.
Tirzepatide is titrated. You generally start low and step up over weeks to months. Under a dose-tiered plan, your bill rises as you climb; under a flat-rate plan it doesn't. A $279 dose-tiered intro that becomes $499 at maintenance can cost more across a year than a $186–$215 flat rate that never moves. Compare providers on the flat-rate providers page.
Before enrolling, ask: Is the price the same at every dose? What's included (visits, labs, shipping)? What happens to the price if I titrate up? What is the cancellation policy?
Not necessarily at the start. Flat-rate means the price doesn't change as your dose increases. Its advantage shows up over a full treatment course and at higher maintenance doses.
No. Some are flat-rate (one price across all doses), others are dose-tiered (price rises with dose). Confirm a provider's current model before enrolling.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved.